Shanghai / Rockville / Baltimore / Bangalore / La Jolla / Management Team Rockville / Beijing / Mumbai / /
Company
V Biosciences / Trevena Inc. / Cardioxyl Pharmaceuticals / Alexion / New Enterprise Associates New Enterprise Associates Inc. / New Enterprise Associates / Zyngenia Inc. / New Enterprise Associates (India) Pvt. Ltd. / New Enterprise Associates (Beijing) Ltd. / MedImmune Ventures Inc. / Cambridge Antibody Technology / Pfizer / Cellective Therapeutics / Cov-X Pharmaceuticals / Ardelyx / Prolifaron / McKinsey & Company / Zosano Pharma / AstraZeneca / Bristol-Myers Squibb / /
Country
United States / China / India / /
Currency
USD / /
Event
M&A / Company Expansion / Employment Change / FDA Phase / Funding / /
Facility
Scripps Translational Science Institute / Skaggs Institute of Chemical Biology / University of California / The Scripps Institute / /
IndustryTerm
venture capital / biotechnology / enterprises that use technology / biopharmaceutical investments / antibody technologies / therapies for various cancers / venture capital firms / /
Skaggs Institute of Chemical Biology and the Departments of Molecular Biology and Chemistry / Scripps Institute / Bristol-Myers Squibb’s Pharmaceutical Research Division / Scripps Translational Science Institute / Next-Generation Biotherapeutics Company Appoints Board of Directors / University of California / San Francisco / /
Person
Robert Garland / Carlos Barbas / Carlos F. Barbas / Joseph Amprey / Peter Kiener / David Hilbert / David M. Mott / /
Position
Professor and Chair / Chief Executive Officer / head / Chief Scientific Officer / Vice President and Head of Research and Development / Chairman / Director / President and CEO / Chief Business Officer / Executive Vice President and Head of Research and Development / Vice President of Research / /
Product
ABthrax / /
ProvinceOrState
Maryland / Indiana / California / /
PublishedMedium
Molecular Biology / /
Technology
genomics / antibodies / biotechnology / drug discovery / antibody technologies / drug development / /
Zyngenia, Inc. Raises $10 Million in Series A Funding - Next-Generation Biotherapeutics Company Appoints Board of Directors, Management Team Rockville, Maryland – November 04, 2009 – Zyngenia, Inc., a privately held